Popular thyroid medication recalled nationwide, FDA warns

The FDA has warned consumers about a nationwide recall affecting certain lots of levothyroxine sodium tablets, a commonly prescribed thyroid medication. The agency said Major Pharmaceuticals distributed the product batches that were found to be “subpotent,” meaning they deliver less medication than intended. The FDA classified the recall as Class II, indicating the affected tablets may cause temporary, reversible health effects. The recall includes specific strengths and lot numbers packaged in 10-count blister packs, sold individually or in cartons containing 10 blister packs; the FDA listed expiration dates and lot identifiers for multiple dosages from 25 mcg through 150 mcg. If a patient has affected tablets, the FDA advises contacting a doctor or pharmacist for guidance and not stopping the medication unless a healthcare provider directs it.